Intensified PEG-L-asparaginase and Antimetabolite-based Therapy for Treatment of Higher Risk Precursor-B Acute Lymphoblastic Leukemia Salzer, W.L., et al. - The Pediatric Oncology Group 9203 pilot protocol was designed to determine the feasibility of delivering 29 biweekly doses of polyethylene glycol (PEG)-L-asparaginase, on a backbone of intensive multiagent antimetabolite-based consolidation and maintenance in higher risk B-precursor acute lymphoblastic leukemia. Between June 1992 and August 1993, 34 patients were enrolled on this limited institution pilot [more...]
